Scientists test One-Shot gene injection to fight rare eye disease
NCT ID NCT07439887
Summary
This early-stage study is testing the safety and initial effects of a single gene therapy injection, called RTx-021, for people with Stargardt disease, a rare genetic condition that causes vision loss. Up to 18 patients aged 16 and older will receive the injection in one eye and be monitored closely for five years. The main goal is to see if the treatment is safe, while also checking for any early signs that it might help improve vision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STARGARDT DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
RayTx Clinical Site
RECRUITINGBakersfield, California, 93309, United States
-
RayTx Clinical Site
RECRUITINGBellaire, Texas, 77401, United States
Conditions
Explore the condition pages connected to this study.